Frankfurt - Delayed Quote EUR

enVVeno Medical Corporation (5HJ.F)

Compare
3.1000
+0.0200
+(0.65%)
As of 8:10 AM GMT+1. Market Open.
Loading Chart for 5HJ.F
DELL
  • Previous Close 3.0800
  • Open 3.1000
  • Bid 3.1800 x --
  • Ask 3.3200 x --
  • Day's Range 3.1000 - 3.1000
  • 52 Week Range 2.7000 - 6.0500
  • Volume 0
  • Avg. Volume 2
  • Market Cap (intraday) 54.982M
  • Beta (5Y Monthly) 1.22
  • PE Ratio (TTM) --
  • EPS (TTM) -1.2200
  • Earnings Date Oct 31, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

enVVeno Medical Corporation, a clinical-stage medical device company, focuses on the development of various bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous diseases. The company's lead product is the VenoValve, a surgical implant being developed for the treatment of venous Chronic Venous Insufficiency. Its VenoValve is implanted in the femoral vein and acts as a one-way valve to help restore proper blood flow in the leg; and enVVe, a non-surgical, transcatheter based replacement venous valve for the treatment of CVI. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.

www.envveno.com

31

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 5HJ.F

View More

Performance Overview: 5HJ.F

Trailing total returns as of 11/19/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

5HJ.F
34.32%
S&P 500
23.56%

1-Year Return

5HJ.F
25.12%
S&P 500
30.56%

3-Year Return

5HJ.F
51.56%
S&P 500
25.28%

5-Year Return

5HJ.F
58.94%
S&P 500
74.71%

Compare To: 5HJ.F

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 5HJ.F

View More

Valuation Measures

Annual
As of 11/18/2024
  • Market Cap

    55.11M

  • Enterprise Value

    10.27M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    1.20

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -37.28%

  • Return on Equity (ttm)

    -58.77%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -21.24M

  • Diluted EPS (ttm)

    -1.2200

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    48.38M

  • Total Debt/Equity (mrq)

    2.42%

  • Levered Free Cash Flow (ttm)

    -9.84M

Research Analysis: 5HJ.F

View More

Company Insights: 5HJ.F

Research Reports: 5HJ.F

View More